🔎 Trials Near Me

Почетна › Akutna mijeloidna leukemija › Њујорк › Buffalo

Kliničke studije za Akutna mijeloidna leukemija u gradu Buffalo, NY

20 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u gradu Buffalo i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Тражи се учесникФаза 3
  • State University of New York at Buffalo, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст 60 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07437950

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 3
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Тражи се учесникФаза 1/2
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05143996

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06672146

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06871410

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Тражи се учесникФаза 1/2
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06969430

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Тражи се учесникФаза 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06846606

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Тражи се учесникФаза 2/3
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Тражи се учесникФаза 3
  • Roswell Park Cancer Institute, Buffalo
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Тражи се учесникФаза 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06001788

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Тражи се учесникФаза 2
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 10. 7. 2026. · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Тражи се учесникОпсервациона студија
  • Roswell Park Cancer Institute, Buffalo
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Тражи се учесникФаза 1/2
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Тражи се учесникФаза 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Тражи се учесникФаза 1
  • Roswell Park Cancer Institute, Buffalo
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2025. · NCT06501196

Studije za Akutna mijeloidna leukemija u drugim gradovima

Ostale studije u gradu Buffalo

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.